公开(公告)号：WO2023072671A1

公开(公告)日：2023-05-04

申请号：PCT/EP2022/078908

申请日：2022-10-18

申请人： BASF SE

发明人： KOCH, Andreas ,  FEHR, Marcus ,  TEGGE, Vanessa ,  DEY, Chandan ,  LE VEZOUET, Ronan ,  RATH, Rakesh ,  POONOTH, Manojkumar ,  WINTER, Christian Harald ,  KHANNA, Smriti ,  CRAIG, Ian Robert ,  GRAMMENOS, Wassilios ,  STAMMLER, Gerd ,  MENTZEL, Tobias ,  DAS, Saikat ,  LUDWIG, Lydia ,  RUDOLF, Georg Christoph

IPC分类号： A01N37/36 ,  A01N37/50 ,  A01N43/20 ,  A01N43/44 ,  A01N43/80 ,  A01N43/82 ,  A01P3/00 ,  C07D205/04 ,  C07D261/08 ,  C07D271/06 ,  C07D305/06 ,  C07C15/12 ,  C07C57/42

摘要： The present invention relates to the use of strobilurin type compounds of formula I and the N- oxides and the salts thereof for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein (also referred to as F129L mutation in the mitochondrial cytochrome b gene) conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, and to seeds coated with at least one such compound.

公开(公告)号：WO2023007188A1

公开(公告)日：2023-02-02

申请号：PCT/GB2022/052013

申请日：2022-07-29

申请人： GREY WOLF THERAPEUTICS LIMITED

发明人： QUIBELL, Martin ,  SHIERS, Jason John ,  FEUTRILL, John

IPC分类号： A61P29/00 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00 ,  A61P37/00 ,  C07C311/21 ,  C07D205/04 ,  C07D257/06 ,  C07D261/08 ,  C07D275/02 ,  C07D305/06 ,  C07D305/14 ,  C07D307/20 ,  A61K31/18

摘要： The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, Formula (I), wherein, the group X-Y is -NHSO2-; Z is a monocyclic or polycyclic cycloalkyl group or a monocyclic or polycyclic heterocycloalkyl group, each of which is optionally substituted by one or more groups selected from haloalkyl, alkyl, alkenyl, alkynyl and -(CR16R17)mR18, where m is 0 to 6; L is a direct bond or a group (CR14R15)n, where n is 1 or 2; R1 is H, CN, Cl or F or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, halo, alkoxy and alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl, SO2NR12R13, heteroaryl, CONR10R11 and alkyl, wherein said heteroaryl group is optionally substituted by one or more substituents selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; R9 is selected from H, alkyl and halo; R10, R11, R12 and R13 are each independently H or alkyl; R14 and R15 are each independently H, halo or alkyl; R16 and R17 are each independently H, halo, haloalkyl or alkyl; and each R18 is independently selected from OH, CN, alkoxy and halo. Further aspects of the invention relate to such compounds for use in the field of immune-oncology and related applications.

公开(公告)号：WO2022204288A1

公开(公告)日：2022-09-29

申请号：PCT/US2022/021560

申请日：2022-03-23

申请人： MODERNATX, INC.

发明人： BENENATO, Kerry E. ,  CORNEBISE, Mark ,  HENNESSY, Edward ,  SEEPERSAUD, Mohindra ,  DANNEMAN, Michael W.

IPC分类号： C07C233/36 ,  C07C233/38 ,  C07C233/40 ,  C07C233/58 ,  C07C233/78 ,  C07C235/10 ,  C07C235/40 ,  C07C237/22 ,  C07C311/05 ,  C07C311/24 ,  C07D205/04 ,  C07D213/74 ,  C07D261/08 ,  C07D271/04 ,  C07D285/10 ,  C07D307/24 ,  C07D309/08 ,  A61K9/00

摘要： The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

公开(公告)号：WO2022155037A1

公开(公告)日：2022-07-21

申请号：PCT/US2022/011226

申请日：2022-01-05

申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  JACOBSON, Kenneth A. ,  JUNG, Young-Hwan ,  WEN, Zhiwei

发明人： JACOBSON, Kenneth A. ,  JUNG, Young-Hwan ,  WEN, Zhiwei

IPC分类号： C07D211/18 ,  C07D249/06 ,  C07D205/04 ,  C07D209/02 ,  C07D211/34 ,  C07D211/70 ,  C07D223/04 ,  C07D255/02 ,  C07D261/08 ,  C07D403/10 ,  A61P29/00 ,  A61P25/00 ,  A61P3/10 ,  A61K31/4192 ,  A61K31/44

摘要： Disclosed are compounds for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, for example, compounds of formulas (I) and (II), wherein R1‑R8, X, Y, Z, X', Y', Z', and A are as defined herein, that are useful in treating an inflammatory such as asthma, cystic fibrosis, and sterile inflammation of the kidney.

公开(公告)号：WO2021255279A1

公开(公告)日：2021-12-23

申请号：PCT/EP2021/066695

申请日：2021-06-18

申请人： AC IMMUNE SA

发明人： GABELLIERE, Emanuele ,  MOLETTE, Jérôme ,  DEHLINGER, Véronique

IPC分类号： C07D263/28 ,  C07C335/16 ,  C07D413/04 ,  C07D233/64 ,  C07D213/64 ,  C07D213/55 ,  C07D309/06 ,  C07D261/08 ,  C07D417/04 ,  A61K31/421 ,  A61P9/00 ,  A61P19/00 ,  A61P25/00 ,  A61P29/00 ,  A61P37/00 ,  C07C2603/10

摘要： The invention relates to novel compounds of formulae (I') and (II') for the treatment, alleviation or prevention of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of the NLRP3 inflammasome pathway. In particular, the component of the inflammasome pathway is a NOD- like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome. More particularly, the compounds of the present invention have the capability to modulate the NLRP3 inflammasome pathway. Further, the compounds of the present invention are suitable for the treatment, alleviation or prevention of diseases, disorders and abnormalities which are responsive to the modulation, in particular decrease, of IL-1 beta and/or IL-18 levels.

公开(公告)号：WO2021092474A1

公开(公告)日：2021-05-14

申请号：PCT/US2020/059522

申请日：2020-11-06

申请人： TERNS, INC.

发明人： FENAUX, Martijn ,  WANG, Yujin ,  ZHONG, Weidong ,  KLUCHER, Kevin

IPC分类号： A61K31/42 ,  A61K31/4545 ,  C07D261/08 ,  C07D413/12

摘要： Provided herein are methods and compositions for treating liver disorders, including without limitation non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient.

公开(公告)号：WO2021062559A1

公开(公告)日：2021-04-08

申请号：PCT/CA2020/051330

申请日：2020-10-02

申请人： CANOPY GROWTH CORPORATION

发明人： AHMAR, Siawash ,  KIM, Jung Yun ,  LAI, Ping Shan ,  OMEARA, Jeffrey Alan ,  TO, Quang Huy ,  DOVE, Peter Martin

IPC分类号： C07C235/60 ,  A61K31/166 ,  A61K31/215 ,  A61K31/277 ,  A61K31/395 ,  A61K31/40 ,  A61K31/41 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/4406 ,  A61K31/495 ,  A61K31/4985 ,  A61K31/505 ,  A61K31/5375 ,  C07C243/38 ,  C07C271/20 ,  C07D213/38 ,  C07D239/26 ,  C07D257/04 ,  C07D261/08 ,  C07D263/32 ,  C07D271/10 ,  C07D295/192 ,  C07D295/26 ,  C07D487/04

摘要： This disclosure relates to carmabinoid derivatives of Formula (1) wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the carmabinoid derivatives. These compounds are potential carmabinoid receptor inhibitors, including CB1 and CB2 receptors. Formula (I)

公开(公告)号：WO2021028810A1

公开(公告)日：2021-02-18

申请号：PCT/IB2020/057495

申请日：2020-08-07

申请人： INORBIT THERAPEUTICS AB

发明人： SHARMA, Rajiv ,  BENTHEM, Lambertus ,  JUDKINS, Robert

IPC分类号： C07C313/04 ,  C07D213/34 ,  C07D213/643 ,  C07D213/68 ,  C07D213/74 ,  C07D215/06 ,  C07D221/20 ,  C07D233/64 ,  C07D239/26 ,  C07D249/08 ,  C07D257/04 ,  C07D261/08 ,  C07D277/42 ,  C07D279/08 ,  C07D307/79 ,  C07D311/58 ,  C07D319/20 ,  C07D333/16 ,  C07D401/12 ,  C07D405/06 ,  C07D405/12 ,  C07D417/12 ,  A61P3/04 ,  A61P3/10 ,  A61K31/192 ,  A61K31/343

摘要： The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions including these compounds for the treatment of metabolic disorders including, for example, diabetes, obesity, metabolic syndrome, fatty liver disease, and bone disorders.

公开(公告)号：WO2021010492A1

公开(公告)日：2021-01-21

申请号：PCT/JP2020/028771

申请日：2020-07-16

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： KAKUUCHI, Akito ,  UMEMURA, Shuhei ,  SVENSSON, Mats ,  RAVINSKY, Anatoly ,  INOYAMA, Daigo ,  KRILOV, Goran ,  TAKAHASHI, Hidenori ,  KONZE, Kyle ,  VERRAS, Andreas ,  CRUMPLER, Simon ,  VALLADE, Maelle ,  MACLEOD, Calum ,  SANDERSON, James N. ,  BULL, Richard J. ,  GAINES, Simon

IPC分类号： A61P25/28 ,  A61P35/00 ,  A61P43/00 ,  C07D261/08 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D498/10 ,  C07D231/06 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/422 ,  A61K31/424 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/53

摘要： The present invention provides KDM5 inhibitor. The compound disclosed herein represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification; or a salt thereof is useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, or Alzheimer's disease and the like.

公开(公告)号：WO2019136147A1

公开(公告)日：2019-07-11

申请号：PCT/US2019/012181

申请日：2019-01-03

申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS ,  ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

发明人： KATZENELLENBOGEN, John, A. ,  POLLOCK, Julie ,  HAECKER, Hans ,  SHARMA, Naina

IPC分类号： A61K31/05 ,  C07D233/64 ,  C07D261/08 ,  C07D263/32

摘要： Di- and triaryl-substituted heteroaromatic compounds have Toll-like receptor inhibitory activity, including at TLR2, TLR4, TLR7, and/or TLR9. Compounds and compositions have applications in the treatment of diseases and conditions mediated by Toll-like receptors and related receptors, such as bacterial sepsis, autoimmune disease, lupus erythematosus, ischemia-reperfusion injury, stroke, metabolic disease, obesity-related metabolic inflammation, gout, and cancer.